# OnCo record tln-372 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tln-372/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tln-372" ;
  schema:name "TLN-372"@en ;
  schema:description "TLN-372 is an experimental small molecule pan-KRAS inhibitor from Treeline Biosciences, in phase 1 trials for KRAS-mutant solid tumours."@en ;
  schema:url <https://onco.cc/drugs/tln-372/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://treeline.bio/medicines>, <https://clinicaltrials.gov/api/v2/studies/NCT07204340>, <https://clinicaltrials.gov/search?intr=TLN-372> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Small molecule pan-KRAS inhibitor" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:companies <https://onco.cc/companies/treeline-biosciences/> ;
  onco:trials <https://onco.cc/trials/nct07204340/> .